Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma

[1]  A. Hauschild,et al.  Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. , 2014, The Lancet. Oncology.

[2]  J. Wolchok,et al.  Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma , 2013, The Journal of experimental medicine.

[3]  Antoni Ribas,et al.  Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. , 2013, The New England journal of medicine.

[4]  H. Scher,et al.  Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  L. Zitvogel,et al.  Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  M. Maio,et al.  Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme , 2013, Cancer Immunology, Immunotherapy.

[7]  I. Salmon,et al.  Single-Center Experience With Ipilimumab in an Expanded Access Program for Patients With Pretreated Advanced Melanoma , 2013, Journal of immunotherapy.

[8]  M. Jure-Kunkel,et al.  CTLA-4 blockade in tumor models: an overview of preclinical and translational research. , 2013, Cancer immunity.

[9]  J. Utikal,et al.  Improved survival with MEK inhibition in BRAF-mutated melanoma. , 2012, The New England journal of medicine.

[10]  C. Garbe,et al.  Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis , 2012, British Journal of Cancer.

[11]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[12]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[13]  Dirk Schadendorf,et al.  Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group , 2012 .

[14]  P. Ascierto,et al.  Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use , 2012, Journal of Translational Medicine.

[15]  F. Barlesi,et al.  Ipilimumab: its potential in non-small cell lung cancer , 2012, Therapeutic advances in medical oncology.

[16]  O. Hamid,et al.  Ipilimumab in Treatment-naive and Previously Treated Patients with Metastatic Melanoma: Retrospective Analysis of Efficacy and Safety Data from a Phase II Trial , 2012, Journal of immunotherapy.

[17]  Axel Hoos,et al.  Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. , 2011, The New England journal of medicine.

[18]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[19]  M. Maio,et al.  Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy) , 2011, Cancer Immunology, Immunotherapy.

[20]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[21]  Jeffrey E Gershenwald,et al.  Final version of 2009 AJCC melanoma staging and classification. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Axel Hoos,et al.  Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria , 2009, Clinical Cancer Research.

[23]  S. Rosenberg,et al.  Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and Hypophysitis , 2007, Journal of immunotherapy.

[24]  P. Leder,et al.  Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. , 2006, Cancer cell.

[25]  S. Rosenberg,et al.  Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  R. Gillies,et al.  Why do cancers have high aerobic glycolysis? , 2004, Nature Reviews Cancer.

[27]  A. Lardner.  The effects of extracellular pH on immune function , 2001, Journal of leukocyte biology.

[28]  J. Manola,et al.  Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  S. Ratner.  Motility of IL-2-stimulated lymphocytes in neutral and acidified extracellular matrix. , 1992, Cellular immunology.